tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew L Kaplan, 1734 are a BUY (83.33%), 347 are a HOLD (16.67%).
Analyst Matthew L Kaplan, currently employed at LADENBURG, carries an average stock price target met ratio of 50.83% that have a potential upside of 42.3% achieved within 510 days.
Matthew L Kaplan’s has documented 63 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on UTHR, United Therapeutics at 25-Feb-2022.
Analyst best performing recommendations are on TGTX (TG THERAPEUTICS).
The best stock recommendation documented was for TGTX (TG THERAPEUTICS) at 5/12/2020. The price target of $44 was fulfilled within 217 days with a profit of $24.06 (120.66%) receiving and performance score of 5.56.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 03-Mar-2023
$19
$13.52 (246.72%)
$19
1 months 9 days ago
(23-Feb-2026)
8/20 (40%)
$13.25 (230.43%)
253
Buy Since 04-Mar-2025
$17
$11.52 (210.22%)
$17
1 months 12 days ago
(20-Feb-2026)
0/4 (0%)
$11.27 (196.68%)
Buy Since 20-Feb-2026
$18
$12.52 (228.47%)
$10
1 months 12 days ago
(20-Feb-2026)
0/2 (0%)
$12.27 (214.14%)
Buy Since 03-Mar-2016
$14
$8.52 (155.47%)
2 months 23 days ago
(09-Jan-2026)
9/17 (52.94%)
$6.26 (80.88%)
163
Buy Since 25-Nov-2025
$16
$10.52 (191.97%)
$16
2 months 23 days ago
(09-Jan-2026)
14/23 (60.87%)
$8.26 (106.72%)
392
What Year was the first public recommendation made by Matthew L Kaplan?
